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Abstract: Polycystic ovary syndrome (PCOS) is the most common, though heterogeneous, 
endocrine aberration in women of reproductive age, with high prevalence and socioeconomic 
costs. The syndrome is characterized by polycystic ovaries, chronic anovulation and 
hyperandrogenism, as well as being associated with infertility, insulin resistance, chronic  
low-grade inflammation and an increased life time risk of type 2 diabetes. MicroRNAs 
(miRNAs) are small, non-coding RNAs that are able to regulate gene expression at the 
post-transcriptional level. Altered miRNA levels have been associated with diabetes, 
insulin resistance, inflammation and various cancers. Studies have shown that circulating 
miRNAs are present in whole blood, serum, plasma and the follicular fluid of PCOS 
patients and that they might serve as potential biomarkers and a new approach for the 
diagnosis of PCOS. In this review, recent work on miRNAs with respect to PCOS will be 
summarized. Our understanding of miRNAs, particularly in relation to PCOS, is currently 
at a very early stage, and additional studies will yield important insight into the molecular 
mechanisms behind this complex and heterogenic syndrome. 
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1. Introduction 
Polycystic ovary syndrome (PCOS) is a complex, multifactorial endocrine disorder affecting 
approximately 5% to 10% of all women of reproductive age [1,2]. PCOS can be defined based  
on three different criteria; the National Institutes of Health (NIH) [3], the European Society of Human 
Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM, 
Rotterdam) [4] and the Androgen Excess Society (AES) [5]. Depending on which criteria are used, as 
well as the studied population, the prevalence of PCOS in women at reproductive age differs from 6% 
to 8%, using the NIH criteria, and up to 20%, using the Rotterdam criteria [2,6,7]. All of the criteria 
include, to some extent, anovulation, hyperandrogenism (clinical and/or biochemical) and polycystic 
ovaries with the exclusion of other androgenic, pituitary or adrenal causes. Aside from being 
associated with infertility and obesity, PCOS is also associated with an increased life time risk of 
developing type 2 diabetes (T2D), insulin resistance, hypertension, oxidative stress, dyslipidemia, as 
well as cardiovascular diseases [5]. The etiology of PCOS is still unclear, but environmental and genetic 
factors may contribute to the pathogenesis of PCOS. It may be explained by the existence of a vicious 
perpetual circle of pathological effects, where androgen excess favouring visceral abdominal fat 
disposition facilitates an increased secretion of androgens by the ovaries and/or the adrenal glands [8]. 
Insulin resistance, a common feature of PCOS, but not a diagnostic criterion of PCOS, leads to 
compensatory hyperinsulinemia with diverse effects on adipose tissue and androgen production. The 
prevalence of insulin resistance in women with PCOS is as high as up to seventy percent [5]. 
MicroRNAs (miRNA) are endogenous, small, non-coding, single-stranded, regulatory RNA molecules, 
composed of 20–24 nucleotides [9]. Processed from larger stem-loop precursor transcripts, miRNAs 
modulate gene expression post-transcriptionally by binding to the 3' untranslated region (UTR) of 
target mRNA, thus inhibiting translation, inducing mRNA destabilization, or both [10]. Recent studies 
have shown that miRNA can be encapsulated in microvesicles [11–14] or be free-circulating [15], and 
they have been isolated from serum [16], plasma [17], urine [19], saliva [11] and semen [19]. 
Little is known about the roles of miRNAs during follicular development, steroidogenesis  
and in PCOS. Several studies on miRNA expression have been done on intact ovaries (chicken [20], 
mice [21–24], pig [25,26], sheep [27] and cattle [28,29]), as well on the different ovarian components, 
such as granulosa cells (mice [30–32], pig [33], horses [14] and human [34,35]), theca cells [32], follicular 
fluid (humans [15,36], cattle [32] and mares [14,37]), cumulus cells (mare [14]), cumulus-oocyte 
complexes (COCs) (cattle [32,38]) and corpora lutea (cattle [39]). 
The possible modes of action for miRNA within the pathophysiology of PCOS have only been 
sparsely investigated, and thus far, only a few miRNA-PCOS studies exist (see Table 1). The purpose 
of this review is to discuss the possible roles of miRNAs in polycystic ovary syndrome, insulin 
resistance and infertility. A greater understanding of the underlying molecular mechanism may help to 
improve diagnosis and treatment of this syndrome. 
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2. MicroRNA Biogenesis and Function 
The biogenesis, function and action of miRNAs has been extensively and well-covered  
elsewhere [51–53]. Briefly, a primary miRNA (pri-miRNA) is transcribed from the genome by RNA 
polymerase II or III, forming an imperfect stem-loop hairpin structure up to several hundred 
nucleotides (nt) in length. A nuclear protein complex consisting of the Drosha enzyme together with 
several other proteins is responsible for the cleavage of pri-miRNA, yielding a precursor miRNA  
(pre-miRNA) transcript of 60–110 nt in length that can be exported out of the nucleus by exportin-5 
(XPO5) into the cytoplasm. Another protein complex containing the enzyme Dicer subsequently 
processes the pre-miRNA further, giving rise to a double-stranded miRNA complex containing  
the mature miRNA and a passenger strand. The mature miRNA associates with the miRNA-induced 
silencing complex (RISC) and targets the 3' untranslated region (3'UTR) of mRNA. Whether the target 
mRNA is degraded, or translation is repressed, depends on the complementarity between the miRNAs 
seed region (positioned from base 2 to base 8–9) and the sequence of the mRNA 3'UTR. Higher 
complementarity more often results in degradation rather than inhibited translation [54]. 
It is well established that protein-encoding genes can be modified through epigenetic mechanisms; 
however, epigenetic modifications have also been observed for a subset of miRNA-encoding  
genes [55–57]. 
Epigenetic modifications refer to stable heritable changes in gene activity and expression that are not 
caused by alterations in the DNA sequence itself. Genes’ availability for transcription and, thereby, their 
expression can be influenced by methylation, chromatin remodeling and acetylation. Furthermore, small 
RNAs, including miRNAs, can also act in an epigenetic manner, causing changes in gene expression [58]. 
It might be possible that identified PCOS susceptibility genes, such as DENND1A [59], which 
interestingly also encodes miR-601 [60], could result in genetic and epigenetic factors overlapping,  
thus influencing miRNA target specificity. A pilot study investigating global methylation in twenty 
PCOS women and 20 BMI- and age-matched controls, using peripheral leukocyte DNA, showed no 
significant differences in the median global DNA methylation percentages [61]. Despite the negative 
result, epigenetics may still play a part in PCOS pathogenesis, since GC and ovary gene-expression 
could be tissue specifically epigenetically modified in PCOS. Thus, PCOS is genetically complex with 
a large degree of heterogeneity and is considerably influenced by environmental and genetic cues, one 
of these being microRNAs. 
3. Serum/Plasma miRNA Biomarkers for PCOS 
Present abundantly in serum, miRNAs could serve as a non-invasive biomarker for PCOS, as  
they have been shown to be stable in serum, are resistant to nuclease activity and are easy to  
detect [62]. It is not known specifically how miRNAs enter serum or whether the miRNAs present in 
serum are disease-specific, since serum is a result of different components secreted by various tissues 
and cells, and identifying their cellular origin can be difficult. Currently, several other biomarkers in 
the serum of PCOS women are used for diagnostic purposes, e.g., luteinizing hormone (LH) and 
androgen concentrations, as well as follicle-stimulating hormone (FSH) [7,63]. 
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A recent case-control study investigating 12 PCOS patients, 12 healthy females and 12 male controls, 
subdivided further based on BMI levels, revealed that obesity significantly reduced the expression of 
four miRNAs selected for evaluation in whole blood: miR-21, miR-27b, miR-103 and miR-155 in 
control women and men, but tending to show an increase in expression in PCOS women. Further 
analysis of their hormone profile showed a positive correlation between serum free testosterone levels 
and miR-21, miR-27b and miR-155. Perhaps, the elevated free testosterone found in the PCOS samples 
could partly explain the observed increase of these miRNAs. Further, bioinformatics analysis and 
target gene analysis revealed that miR-21, miR-27b, miR-103 and miR-155 could be involved in hormone 
metabolism, as well as reproductive cellular processes [41]. 
Using miRNA arrays, the expression of serum miRNAs in patients with PCOS compared to  
age-matched controls has been evaluated [43]. Following an initial miRNA profiling based on a 
relative two-fold change in expression levels, nine miRNAs (miR-222, miR-16, miR-19a, miR-106b, 
miR-30c, miR-146a, miR-24, miR-186 and miR-320) were chosen for further analysis. The expression 
levels for eight of the miRNAs were upregulated in serum from PCOS patients, whereas miR-320 
displayed decreased expression in the PCOS subjects. However, following Q-PCR validation of the 
nine miRNAs’ expression in the entire study population (n = 68 PCOS, n = 68 controls), only miR-222, 
miR-146a and miR-30c remained significantly increased in the PCOS patients’. Sensitivity and specificity 
analysis, using receiver operating characteristic (ROC) curves and area under the curve (AUC), revealed 
that a combination of the three miRNAs was able to distinguish between the PCOS and controls. In 
addition, correlation analysis adjusted for age and BMI showed that miR-222 strongly correlated 
positively with serum insulin levels in PCOS women [43]. Interestingly, upregulated expression levels 
of miR-222 have also been associated with type 2 diabetes [64] and gestational diabetes mellitus [65]. 
Further, miR-146a correlated negatively with serum testosterone in PCOS women [43]. Decreased 
miR-146 has been linked to inflammation and insulin resistance in T2D individuals [66]. An interesting 
observation made by Long et al. was that most of the miRNAs present and differentially expressed in 
ovarian tissue from PCOS women were not released into the blood and, therefore, were not altered in 
PCOS serum [43]. 
In conclusion, identification of distinct miRNAs present within the circulation would prove a useful 
tool for diagnosis and perhaps treatment of PCOS. Comparing the miRNA profile of PCOS patients to 
healthy controls reveals that miRNAs might contribute to the pathogenesis. Indeed, miR-21, miR-27b 
and miR-103 are associated with PCOS, as well as metabolic features, such as obesity, T2D, low-grade 
inflammation and adipogenesis dysfunction. Furthermore, insulin sensitivity and the suppression of 
androgens have been associated with miR-222 and miR-146a, respectively. Profiling of serum miRNAs 
does not necessarily reflect the more local changes within the ovary, and the functional role and 
significance of miRNAs in blood from PCOS patients still need to be determined. 
4. MicroRNAs as Biomarkers for PCOS Based on Follicular Fluid Content 
Investigation of miRNAs in follicular fluid might reveal new targets for improving intrafollicular health 
and/or restoration of ovulatory dysfunction in PCOS. During oocyte retrieval, follicular fluid is easily 
available and could serve as an optimal, less-invasive source for miRNAs. Recent research has identified 
miRNAs in human [15,36] and mare follicular fluid [14]. Follicular fluid is in close proximity to the oocyte 
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and consists of blood plasma components crossing the blood-follicular barrier, secretions from granulosa 
and theca cells and serves as an important microenvironment for the maturation, development and quality 
of the oocyte. Follicular fluid contains hormones, such as FSH, LH, GH, estrogens and androgens, growth 
factors, including TGF-, inhibin, activin, anti-Müllerian hormone, as well as anti-apoptotic factors, such 
as Fas-ligands, and, lastly, proteins, peptides, amino acids and nucleotides [67]. 
Recently, two miRNA profiling studies using follicular fluid from PCOS women have been 
published, although with conflicting results [15,36]. Roth et al. performed a miRNA profiling study on 
PCOS patients fulfilling the Rotterdam criteria, undergoing IVF and compared them to healthy fertile 
oocyte donors. They found that 29 miRNAs were significantly differentially expressed between PCOS 
samples compared to controls. Out of the 29 miRNAs, hsa-miR-9, hsa-miR-18b, hsa-miR-32,  
hsa-miR-34c and hsa-miR-135a expression showed a significant increase in the PCOS samples 
compared to the controls. Subsequent cluster analysis classified the selected miRNAs into two distinct 
groups containing only PCOS patients in one of them, while the other group had all of the controls along 
with two PCOS samples, thus reflecting the heterogenic nature of PCOS [36]. In addition, based on  
in silico target site predictions and the association with PCOS phenotypes for the upregulated miRNAs, 
an mRNA expression profile of interleukin 8 (IL8), synaptotagmin I (SYT1) and insulin receptor 
substrate 2 (IRS2) in follicular fluid was further performed. All five miRNAs negatively correlated with 
the mRNA expression of IL8, SYT1 and IRS2 in the PCOS population, thus suggesting an inhibitory 
mode of action [36]. Sang et al. also isolated over 100 different miRNAs in follicular fluid from women 
with PCOS and healthy controls undergoing intracytoplasmic sperm injection (ICSI) treatment [15]. For 
the purpose of this review, not all of the identified miRNAs will be stated here, but a selection will be 
discussed. The PCOS patients were diagnosed based on the AES criteria. Construction of a small RNA 
library from pooled follicular fluid samples followed by sequencing revealed an abundant expression of 
mature miRNAs in follicular fluid. In accordance with a previous study [68], the eleven most  
highly-expressed miRNAs, hsa-miR-483-5p, -674-3p, -191, -193b, -320, -520c-3p, -24, -132, -146a,  
-222 and -1290, were present both free in solution and within micro-vesicles [15]. When comparing the 
miRNAs found in the follicular fluid of PCOS patients and healthy controls, only miR-132 and  
miR-320 showed a significantly lower expression level in the PCOS patients [15]. Specifically 
regarding miR-320, another study using follicular fluid and granulosa cells (GCs) from women with 
PCOS showed that the expression of miR-320 was higher in the PCOS group compared to controls, which 
contrasts the findings by Sang et al. [48]. Of interest, although miR-132 and miR-320 were observed to be 
decreased in the study by Sang et al., this was not observed by Roth et al., perhaps explained by the 
heterogenic nature of PCOS and the studied populations, differences in the control groups used or the 
general methodology. Thus, more studies are needed to resolve these divergent findings. 
Interestingly, a recent genome-wide association study (GWAS) on the etiology of PCOS [69] 
identified one SNP in the intronic region of the high mobility group AT-hook 2 (HMGA2) gene and 
one SNP in the intergenic region near the Ras-related protein Rab-5B (RAB5B) gene. These genes are 
predicted targets of miR-132 and miR-320, respectively [15]. It remains to be elucidated if these genes 
in fact are true targets for these miRNAs and what their functions are in PCOS. 
Noteworthy in the context of miRNAs serving as biomarkers, studies have shown that the follicular 
fluid content of different proteins and hormones, as well as follicular cell metabolism are altered in 
women of advanced maternal age [70]. Thus, one may speculate that the miRNA content, found in 
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follicular fluid might also change in an age-dependent manner. MicroRNA profiling based on follicular 
fluid obtained from younger (median age 29.7, n = 3) and older (median age 40.3, n = 3) women 
undergoing IVF revealed that hsa-miR-21 was only present in young women’s follicular fluid, while 
hsa-miR-99b-3p, hsa-miR-134 and has-miR-190b were only found in, or expressed at higher levels, in 
the older women’s follicular fluid. Validation of the miRNA array profiling with more samples (n = 8 
young vs. n = 6 old) by qRT-PCR followed the same pattern [13]. However, miRNAs found to be 
associated with reproductive aging in other studies were not altered in the study by Roth et al. 
Nevertheless, target gene predictions of the miRNA expression profiles found in follicular fluid in the 
studies by Roth and Sang suggest pathways involved in reproduction pathways, reproductive aging, 
carbohydrate metabolism, steroid synthesis, cellular growth, beta cell function, insulin signalling and 
cell communication [15,36]. 
In conclusion, comparing the miRNAs found in follicular fluid to the miRNAs found in the blood 
reveals the common occurrence of miR-186, miR-21, miR-155, miR-103, miR-19a and miR-16, 
although with different expressions levels and significance associated with PCOS. Moreover, the 
miRNA profile of follicular fluid varies between studies, highlighting that PCOS is a complex and 
heterogenic syndrome. Interestingly though, increased expression of miR-146 was found in serum 
from PCOS patients and also in follicular fluid by Roth et al. and Sang et al., respectively. Adding to 
this, miR-222 and miR-24 were also found to be highly expressed in follicular fluid, as well as 
identified in PCOS serum. A differential expression, albeit in different directions, was observed for 
miR-320. Taken together, this still warrants further studies. 
5. Possible Role for miRNA in the Abnormal Follicular Development and Function in PCOS 
Many different theories have been brought forth in an attempt to explain the mechanisms responsible 
for the impaired ovulation, abnormal follicular development and excessive follicle formation commonly 
found in women with PCOS, but with varying results. An altered appearance and function of granulosa 
cells (GCs) with respect to FSH, LH and androgens has been proposed. Defects in steroidogenesis by 
the theca cells (TCs) and increased activation of primordial follicles, abnormal expression of  
anti-Müllerian hormone, increased follicle survival and/or a decreased apoptosis rate have also been 
reported. Many of the factors involved in these processes are still unknown and the mechanisms 
unestablished [71]. 
Total ovarian RNA from several species has been subjected to next-generation sequencing and 
cloning-based approaches. Thus, this has established that miRNAs are highly expressed in the ovaries 
of mice [21,23,25,28,29]. Furthermore, in mice, the degree of miRNA expression in the ovaries shows 
a genomic bias, with the X chromosome accounting for a high number of the miRNAs [72]. 
To investigate the miRNA profile in PCOS, different animal models have been used depending on 
the mechanisms being investigated. In a study by Hossain et al., a rat model exhibiting both ovarian 
and metabolic characteristics of PCOS was used to study the miRNA expression. This PCOS model 
utilized exposure to 5-dihydrotestosterone (DHT) to mimic the hyperandrogenic phenotype observed in 
human PCOS. Analysis of the ovaries from the DHT-induced rat PCOS model, using preformatted 
array plates, showed that 24% (equal to 79) out of 346 potential miRNAs were differentially expressed 
in the DHT-treated ovaries compared to untreated ovaries. Of the altered miRNAs found in the  
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DHT-treated ovaries, 17 miRNAs were downregulated, whereas 72 miRNAs were upregulated 
compared with the control ovaries. A further characterization of the presence of miRNAs within  
the different ovarian compartments revealed that miR-222 was solely found in theca cells [24]. Thus, 
altered miRNA profiles seem to constitute part of the PCOS picture, even though complementary 
studies in human donor material needs to be added in order to tease out whether the alterations is a 
cause or consequence of PCOS. 
More extensive studies of miRNAs in GCs have been performed compared to that of other ovarian 
cell types. Investigating the role of miRNAs for balancing apoptosis and proliferation, Sirotkin et al. 
found that apoptosis was induced in human GCs following transfection with 80 different miRNA 
constructs mimicking endogenous precursor miRNAs. Specifically, 11 of the miRNA constructs were 
associated with the accumulation of the apoptosis marker Bax and apoptosis induction [34]. The same 
study also investigated the proliferation of human GCs using proliferating cell nuclear antigen (PCNA) 
protein as a marker and the same miRNA constructs and found increased PCNA protein expression 
after transfection with eleven miRNAs constructs [34]. 
Apoptosis has also been induced in cultured human luteinized GCs following overexpression  
of pre-miR-23a. In this instance, anti-apoptotic X-linked inhibitor of apoptosis protein (XIAP) was 
reported to be downregulated, both at the transcriptional and translational level. XIAP prevents 
apoptosis by means of pro-apoptotic caspase inhibition; accordingly, the level of the cleaved form of 
caspase-3 was upregulated [73]. 
Studies on the apoptosis rate in mouse GCs, revealed that knockdown of miR-21 in vivo in equine 
chorionic gonadotropin (eCG)-treated mice resulted in an increased apoptosis rate. Furthermore, a 
decreased ovulation rate, as defined by the number of cumulus-oocyte complexes recovered from the 
oviduct, of the mice was shown [31]. 
Another miRNA of interest is miR-376, involved in primordial follicular assembly. Studies in fetal 
mouse ovaries show that miR-376a directly binds to the 3'UTR mRNA sequence of PCNA, thereby 
causing a reduction of PCNA on both mRNA and protein levels [74]. In this regard, an additional 
study in mouse shows that increased expression of miR-143 suppresses GC proliferation, thus inhibiting 
the formation of primordial follicles [75]. As miR-143 was also one of the differentially-expressed 
miRNAs found in follicular fluid from women with PCOS by Roth et al. [36], it constitutes a 
promising candidate for future investigations. 
Further studies of GC proliferation in the mouse suggest miRNA involvement in the transforming 
growth factor- (TGF-)/Smad4 pathway, which is important for regulating cell growth, differentiation 
and development. In a study of isolated GCs from mouse pre-antral follicles treated with TGF-1,  
it was found that the expression of miR-712, miR-224 and miR-764-3p was upregulated, while  
13 miRNAs (including miR-143, miR-383 and miR-320) were downregulated. Specifically, the 
induction of GC proliferation through TGF-1 was mainly mediated by the upregulated miR-224. 
Blocking the TGF- receptor attenuated this effect, and Smad4 was identified as a target of miR-224. 
Thus, the increased TGF-1-induced proliferation rate in GCs was mediated partly though the  
TGF-/Smad pathway [47]. Of note, both Sing et al. and Roth et al. identified miR-224 in follicular 
fluid [15,36]. However, more studies need to be performed before concluding if the same pathway is 
affected in human folliculogenesis. 
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In addition, mmu-miR-224 has been identified as targeting pentraxin 3 (ptx3), an important protein 
involved in cumulus expansion [46,76]. Overexpressing mmu-miR-224 in the mouse cumulus oocyte 
complex indeed inhibited Ptx3 protein expression [46]. This miRNA could be of interest for further 
examination, as PTX3 gene expression has been found highly upregulated during ovulation in GCs 
isolated from women following controlled ovarian stimulation. Perhaps, PTX3 levels could serve as a 
marker for final oocyte maturation [77]. Further, with regards to PCOS, PTX3 mRNA expression in 
PCOS patients correlates with fertilization processes [78] and could possibly be used as a biomarker 
for oocyte quality. However, consensus has not yet been reached; a study report that plasma PTX3 
levels in women with PCOS is reduced [79], whereas yet another study shows PTX3 levels to be 
elevated in PCOS and positively correlated with insulin resistance [80]. As such, more research needs 
to be done before reaching a conclusion on the role of miR-224 in PCOS and whether altered PTX3 
levels are a cause or consequence of the disease. 
Stages of early and progressive atresia in follicles have been assessed in pigs using a microarray 
approach [33]. A decreased rate of follicular atresia has been observed in cultured human ovarian tissue 
from PCOS follicles [81]. It was found that miR-26b, an miRNA also found in human follicular  
fluid [15], was upregulated during follicular atresia. When further investigating possible functions of 
miR-26b through culturing the porcine GCs and transfecting with miR-26b mimics, it was shown that the 
apoptosis rate increased. It followed that miR-26b targeted and repressed ataxia telangiectasia mutation 
(ATM) at the mRNA level, a protein known to coordinate DNA repair. TUNEL assays performed after 
miR-26b transfection showed an increase in DNA breaks, thus explaining the increase in apoptosis [33]. 
Taken together, altered expression of ovarian miRNAs might play a role in the processes determining 
the fate of granulosa cells (proliferation and differentiation vs. apoptosis), and this might lead to the 
hyper-proliferating granulosa cells, as seen in PCOS. The roles and mechanisms of miR-224, miR-320 
and miR-383 in GCs during folliculogenesis in general and in PCOS remain unknown. 
6. Infertility, an Important Feature of PCOS and the Involvement of microRNAs 
The importance of microRNAs in regards to fertility, follicle development and oocyte maturation 
has become evident using the Dicer1 knock-out mouse. Dicer1 is an, RNase III enzyme involved in the 
processing of pre-miRNA into the shorter miRNA duplex [82] and, thus, important for microRNA 
biogenesis. Knock-out of Dicer results in lethality early in development, while conditional ovarian 
tissue-specific knock-out models of Dicer result in infertile female mice, low ovarian weight, low 
ovulation rate, abnormal estrous cycles and dysregulation of development-related genes. Furthermore, 
defects in meiotic progression due to defective spindle formation, defects in the development and 
function of the ovarian corpus luteum, due to abnormal angiogenesis in the corpus luteum, and the 
formation of fluid-filled cysts on the oviducts are also evident in the conditional knock-out model. 
Studies describing Dicer knock-outs have recently and extensively been reviewed elsewhere [83–85] 
and will not be described further. 
Isolated blastocysts from women referred to IVF, either due to polycystic ovaries or male  
factor infertility, revealed that the expression of six miRNAs (hsa-let-7a, hsa-miR-19a, hsa-miR-19b,  
hsa-miR-24, hsa-miR-92 and hsa-miR-93) was significantly decreased in the blastocysts from the 
PCOS patients compared to blastocysts from healthy fertile donor oocyte controls [40]. Heatmap 
Genes 2014, 5 694
 
analysis for the expression level of the six miRNAs showed that the heatmap profile of women with 
polycystic ovaries was different from that of the fertile donors and women from couples having male 
factor infertility; the latter shared a close resemblance to each other. The morphology of the blastocysts 
was similar for the three groups. Further, three predicted target genes were chosen for mRNA 
expression. The expression of the miR-19a target gene ARIH2, important for cell differentiation, showed 
an upregulation only in the PCOS group, with a simultaneous decrease in miR-19a. Likewise, the 
KHSRP and NFAT5 genes, encoding an mRNA decay promoting factor and a transcription factor, 
respectively, and both targets for miR-24, showed an upregulation in both of the infertile groups, 
together with an observed decrease of miR-24 [40]. With the exception of hsa-let-7a, all of the miRNAs 
were also detected in human follicular fluid, but the expression levels displayed a great variation, never 
reaching a significant difference between PCOS women and healthy controls. 
Maternal age-related infertility and miRNA expression levels were investigated using human 
blastocysts derived from younger (mean 26.4 years) and older (range 40–44 years) oocyte donors [86]. 
Out of 42 differentially-expressed miRNAs, the majority were increased in older women. Eleven 
miRNAs (miR-15b, miR-18a, miR-184, miR-195, miR-20b, miR-212, miR-222, miR-367, miR-515-5p, 
miR-518a-3p and miR-93) were only present in the older study population, and miR-93 expression was 
particularly increased in blastocysts showing abnormal chromosomes [86]. Maternal aging is a risk 
factor associated with human infertility, which is associated with an altered miRNA profile. 
7. MicroRNAs and Ovarian Hormone Synthesis 
The ovarian cycle is controlled by hormones released from the hypothalamic-pituitary-ovarian  
axis, and an altered secretion has been observed in women with PCOS. Although androgen excess is  
a prominent feature of PCOS, androgens have proven important for female reproduction, since a lack 
of androgen receptors and, hence, the inability of androgens to stimulate their targets, result in 
reproductive defects [87–89]. The level of free, and, thereby, bioavailable and active, testosterone is 
only around 1%–2%, whereas the rest is either bound to sex-hormone binding globulin (SHBG) or 
albumin. Women with PCOS often display low levels of SHBG [90], and in addition to this, 
hyperinsulinemia can also decrease the level of SHBG [91], thus increasing the levels of bioactive 
testosterone. Within the ovaries, theca cells synthesize androgens, when stimulated by luteinizing 
hormone (LH). Ovarian GCs, under the influence of follicle-stimulating hormone (FSH), produce the 
enzyme, aromatase, which is able to convert testosterone and androstenedione to estrogen. Within 
peripheral adipose tissue, aromatase also converts testosterone to estrone. 
The influence of specific miRNAs on the release of steroid hormone from ovarian cells has been 
demonstrated by several cell studies across a variety of species. 
Cultured primary human ovarian GCs transfected with 80 different miRNA overexpression constructs 
revealed that 36 miRNAs correlated with inhibited progesterone release, while 10 miRNAs increased 
the release of progesterone after transfection. Moreover, 57 of the constructs inhibited the release of 
testosterone and 51 miRNA constructs correlated with reduced estradiol secretion. Only miR-107 was 
found to increase the release of testosterone [35]. 
Transfection with miRNA-24 mimics in the steroidogenic human granulosa-like tumor cell line, 
KGN, resulted in decreased estradiol secretion, while transfections with miR-132, miR-320, miR-520c-3p 
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and miR-222 mimics increased estradiol secretion. Moreover, miR-24, miR-193b and miR-483-5p 
transfections also correlated with decreased secretion of progesterone [15]. 
Studying ovulation and luteinization, miRNA expression profiles were investigated in mice that had 
been stimulated with eCG to induce follicular development. Ovulation was then induced using human 
chorionic gonadotropin (hCG) injection after 46 h of eCG-stimulation. The following microarray analysis 
was based on isolated mouse mural GCs collected previous to and 4 h post hCG-stimulation. The 
microarray analysis revealed that 13 miRNAs were differently expressed between the two different time 
points, with miR-21, miR-132 and miR-212 being specifically upregulated by hCG. It is known that hCG 
and LH upon binding to the LH receptor activate the cAMP signal transduction pathway. In order to 
elucidate the role of miR-132 and miR-212 in ovulation and luteinization, mural GCs were exposed to 
cAMP in vitro. Confirming in vivo results, cAMP induced the expression of the two miRNAs in vitro. 
However, knockdown of miR-132 and miR-212 did not affect cAMP-induced steroidogenesis in vitro [30]. 
7.1. MicroRNAs Targeting Steroid Receptors 
Increased expression of androgen receptors (AR) has been identified in women with PCOS [92], 
and even though androgen excess is an important feature in the pathogenesis of PCOS, androgens and 
their receptors have proven important for normal ovarian function, as observed in the AR-knockout 
model, having defective folliculogenesis. AR is expressed predominantly in GCs of growing ovarian 
follicles [93], but can also be found in other reproductive cells, as well as in non-reproductive tissues. 
The luteinizing hormone/chorionic gonadotropin receptor (LHCGR), as well as miR513a-3p are 
both expressed in human ovarian GCs. LHCGR is a predicted target of miR-513a-3p, and downregulation 
of LHCGR expression by miR-513a-3p has been observed [94]. A next generation sequencing approach 
in human GCs identified three novel and previously un-annotated miRNAs. The three miRNAs; 
miRNA-7973-1, miRNA-7973-2 and miR-548ba, were predicted to originate from the FSHR and 
CYP19A1 genes, respectively. Furthermore, one of these miRNAs was predicted to target the AVBR2B 
and SMAD2 genes, which are involved in FSHR mRNA expression in GCs [95]. Isolated GCs from 
oocyte retrieval in women undergoing IVF have been shown to express miR-125b. Using a GC-specific 
androgen receptor (AR) KO mouse model, the expression of the anti-apoptotic miR-125b was enhanced 
by extra-nuclear AR signaling. The increase was found likely to contribute to androgen-induced follicular 
survival by a decrease in follicular atresia. Secondly, the protein levels of FSHR, but not mRNA, were 
found to be increased by androgens, potentially contributing to follicles being more sensitive to FSH, 
hence stimulating androgen-mediated follicle growth [96]. 
miR-136-3p expression was increased in a study of rat ovaries and isolated GCs following an 
ovulatory dose of LH-human chorionic gonadotropin (hCG). Simultaneously, mRNA levels of the 
hCG receptor (LHR) were reduced, and thus, miR-136-3p was suggested to target LHR [97]. Another 
study in rat following hCG stimulation revealed an increase in ovarian miR-122 with a concomitant 
decrease in LHR mediated via the cAMP/PKA pathways. In this instance, though, a simultaneous 
increase in LHR mRNA binding protein (LRBP) was also found, at both the mRNA and protein level. 
This observation was also confirmed using a similar approach with human GCs [98]. 
Estrogen receptor alpha knockdown adult female mice display cystic ovaries, high levels of LH and 
ovulation abnormalities. The estrogen receptor 1 (ESR1) gene is a predicted target for miR-222, miR-193b 
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and miR-520c-3p [99]. At least in studies of breast cancer, miRNA-222 has been shown to negatively 
regulate the estrogen receptor alpha at the protein level [45], while miR-193b regulates estrogen  
signaling [100]. Interestingly, miR-222, -520c-3p and 193b can influence not only the estrogen receptor, 
but also steroid secretion, making these miRNAs very interesting candidates for further studies. It is 
possible that an abnormal expression of estrogen receptors or aberrant estrogen receptor signaling might 
contribute to the pathogenesis, the abnormal follicular development and the infertility seen in PCOS [101]. 
7.2. MicroRNAs Targeting Steroid Synthesis Enzymes 
The biosynthesis of steroid hormones relies on different genes, including StAR, CYP19, CYP11A 
and CYP17. Thus, miRNAs affecting these genes might play a role in the perturbed homeostasis of 
steroid hormones commonly seen in PCOS. In the search for PCOS candidate susceptibility genes, 
results regarding CYP11A are presently conflicting. One large patient-based study find no associations 
linking CYP11A to the disease [102] while others report a relationship between CYP11A promoter 
variants and raised testosterone levels [103–105]. 
The production of estrogens relies, in part, on the enzyme, aromatase. Aromatase is encoded by  
the CYP19A1 gene, with tissue-restricted expression, e.g., within the ovaries, where the enzyme is 
ultimately produced in GCs under the influence of FSH [106]. To our knowledge, studies investigating 
potential miRNAs regulating CYP19A1 expression in GCs have only been performed in pigs and mice. 
When GCs isolated from porcine ovaries were treated to overexpress miR-378 at high levels, a 
subsequent decrease was observed of aromatase protein following and, hence, reducing estradiol 
concentrations in the media of the cultured GCs [107]. Another study in mouse GCs reveals that  
miR-181a also targets CYP19A1, thereby downregulating estrogen biosynthesis [108]. 
On the other hand, several miRNAs have also been shown to associate with increased estradiol 
levels. Following overexpression of miR-133b in mice GCs stimulated with FSH, estradiol levels were 
increased with a simultaneous increase of both CYP19A1 and StAR mRNA levels [109]. A predicted 
target of miR-133b was the forkhead box L2 (Foxl2), which functions as a transcriptional repressor  
of CYP19A1 and StAR. Furthermore, the FOXL2 gene has been shown to be vital for female 
reproduction [110,111]. In accordance, loss-of-function studies using miR-133b inhibitors decreased 
the estradiol concentration in a KGN cell line, as well as in the mouse GCs. Thereby, miR-133b  
may play a role in FSH-induced estrogen secretion by indirectly increasing the expression of the 
steroidogenesis-associated genes StAR and CYP19A via repression of Foxl2 [109]. Increased release 
of estradiol from mouse GCs via an enhanced expression of CYP19A1 has also been reported following 
upregulated levels of miR-383 in a dose-dependent manner. The mechanism of action for miR-383 was 
predicted to be mediated through an inhibition of the transcription factor RBMS1 gene and its 
downstream target c-Myc, hence influencing estradiol release in GCs. No effect on progesterone 
production, GC proliferation or apoptosis was reported [50]. As upregulated miR-383 levels have 
previously been detected in women with PCOS 34, this miRNA could be interesting to study further, 
as, perhaps, it may be a mediator of the pathologically-elevated levels of estrogen commonly detected  
in women carrying the disease. A third study shows that the level of CYP19A1 mRNA increased in 
mouse GCs treated with either miR-224 or TGF-1, without any effect on the CYP11A1 mRNA level.  
Overexpression of miR-224 resulted in increased estrogen release, while knockdown of miR-224 had 
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the opposite effect, indicating that miR-224 could play a part in steroid production. One predicted 
target gene of miR-224 is Smad4, and miR-224 was able to negatively regulate Smad4 (a mediator of 
TGF  signaling), thus regulating GC proliferation and estradiol release [47]. Interestingly, studies 
have revealed that miR-224 transcription in mouse GCs is regulated by the two transcription factors 
Tp53 and the p65 subunit of NF, through transcriptional inactivation of the GABRE (miR-224 host 
gene) promoter. Smad4 is targeted by miR-224, and knockdown of Tp53 and NF p65 led to lower 
Smad4 protein levels, while GC proliferation and estradiol production increased [112]. 
Understanding how miRNAs contribute to androgen production has great potential with respect to 
steroid-related disorders, such as PCOS. 
8. MicroRNAs, Insulin Sensitivity and Insulin Resistance 
Most women with PCOS suffer from some degree of insulin resistance and hyperinsulinemia. Even 
though insulin resistance is not a diagnostic feature of PCOS, as many as 38%–88% of PCOS women 
are either found to be obese or overweight. There is a disadvantageous interaction between obesity, 
insulin resistance and PCOS, with obese women with PCOS being more insulin resistant. Studies in 
regard to lean women with PCOS and the presence of insulin resistance have proven inconsistent 
(reviewed by [113]). 
In a study of primary adipocytes from women with PCOS, it was found that the level of GLUT4, 
the major insulin-dependent glucose transporter, was positively correlated with insulin sensitivity. 
Further, miR-93 was predicted to target GLUT4, and their respective expression levels were inversely 
correlated. This correlation was further supported by overexpression and knockdown studies of  
miR-93. However, although miR-93 might play a role in determining insulin sensitivity via GLUT4, 
miR-93 itself was associated with PCOS status [44]. 
Hyperinsulinemia could potentially contribute to the hyperandrogenism found in women with 
PCOS. Insulin has been shown to activate the enzyme CYP17 and work synergistically with LH  
within porcine theca cells to increase cAMP concentration, thus leading to an activation of StAR  
and the production of androgens [114]. Moreover, insulin has also been observed to induce follicular  
arrest [115,116]; however, the mechanisms behind follicular arrest are not fully understood. An 
improvement of insulin sensitivity may result in a more controlled glucose metabolism, reduced 
androgen levels, better ovulation rates and, hence, improved fertility. 
Since their discovery, several miRNAs have been identified and found to be differentially regulated 
in a variety of animal models of diabetes. In a hyperglycaemic, T2D rat model, miR-222 and miR-27a 
were shown to be upregulated in adipose tissue [117]. Additionally, miR-29 paralogs have also been found 
upregulated in adipose tissue in a diabetic mouse model and associated with increased insulin 
resistance in the mouse-derived 3T3-L1 adipocyte-like cell line [118]. In another study, 3T3-L1 adipocytes 
were rendered insulin resistant by treatment with high levels of glucose and insulin. It followed that the 
expression levels of miR-320 displayed a 50-fold increase. The insulin sensitivity was then restored 
upon the addition of anti-miR-320 oligos, with a resulting upregulation of GLUT4 expression and 
increased insulin-mediated glucose uptake [49]. If the pathway for miR-320 is similar in humans, it 
could potentially serve as a target to improve insulin sensitivity, as miR-320 has been found to be very 
abundant in follicle fluid from women with PCOS [15]. 
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To improve insulin sensitivity in PCOS women, insulin sensitizing drugs, such as metformin, are 
prescribed. Metformin decreases hepatic glucose production while stimulating glucose uptake in  
insulin-sensitive tissues and improves lipid metabolism. Taken together, the medication decreases 
insulin resistance with several positive effects on androgen levels, ovulation and, subsequently,  
fertility [119]. The expression pattern of certain miRNAs might also be regulated by the administration 
of metformin. The expression level of miR-221 and miR-222 was found to be elevated in the internal 
mammary arteries (IMAs) of subjects with T2D, while patients on metformin displayed an expression 
level similar to non-diabetic patients [120]. Others have studied the effects of metformin on altered 
miRNA expression in various cancers [121,122]. 
Metformin is capable of changing global miRNA expression patterns, as shown in the 
aforementioned studies in metformin-treated cancer samples. Furthermore, the finding that metformin 
is able to induce Dicer expression [123] might establish a link between the metabolic action of the drug 
and altered miRNA expression. 
9. Conclusions and Further Perspectives 
In summary, the pathophysiology of PCOS is not easily summarized, since it involves areas within 
gynaecology, endocrinology and diabetology. Depending on which PCOS criteria are used, different 
phenotypes arise and, in addition, the varying networks of microRNAs contribute to the complexity. 
The notion that one miRNA may have several mRNA targets and that one mRNA 3'UTR may be 
regulated by multiple miRNAs complicates matters further. As such, our current knowledge of how 
miRNA might fine-tune the events leading to increased ovarian cell proliferation and/or apoptosis, 
abnormal folliculogenesis, altered steroidogenesis or adipocyte dysfunction is not yet complete,  
and more functional miRNA-mRNA studies are needed. With the current knowledge, it is not possible 
to distinguish whether an altered miR expression profile is the cause or a consequence of PCOS. 
However, it appears that microRNAs could be used as biomarkers distinguishing PCOS patients  
from normal menstruating women or to identify sub-phenotypes within this heterogeneous syndrome. 
Furthermore, insight into the interplay between epigenetic regulation and miRNAs leading to an 
altered miRNA expression could perhaps help to explain the pathogenesis behind the disease. The 
dynamic expression of miRNAs has been shown to be influenced by several factors, such as LH/hCG, 
FSH, androgens and cAMP in vitro. Caution needs to be exerted when interpreting in vitro and in vivo 
findings, since miRNAs might be regulated differently by the two systems. Although miRNAs have 
been identified in the ovary and different ovarian compartments, as well as in the circulation, little  
is known about the roles of miRNA in PCOS pathology. Of interest, PCOS subjects are often 
undergoing IVF treatment and/or receiving metformin, which might affect the miRNA expression 
profile. Currently, only a limited number of studies have aimed to extensively profile miRNA 
expression and function within a PCOS study population, and the results are at times, contradictory. 
However, it follows that a resilient motivation should arise to further research the actions and 
regulations of miRNAs to clarify their role in PCOS. 
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